Aptus Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 1.00 Cr
as on 23-10-2024
- Company Age 14 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 Cr
as on 23-10-2024
- Satisfied Charges ₹ 3.00 Cr
as on 23-10-2024
- Revenue 32.27%
(FY 2023)
- Profit 140.83%
(FY 2023)
- Ebitda 97.49%
(FY 2023)
- Net Worth 28.50%
(FY 2023)
- Total Assets 55.27%
(FY 2023)
About Aptus Pharma
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹3.00 Cr. The company has closed loans amounting to ₹3.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jyotiben Chandarana, Riddhish Tanna, Tejash Hathi, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230GJ2010PTC061957
- Company No.
061957
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Aug 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Aptus Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tejash Hathi  | Managing Director | 12-Aug-2010 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Riddhish Tanna | Director | 06-Feb-2024 | Current |
| Chetan Lalseta | Director | 06-Feb-2024 | Current |
| Jyotiben Chandarana | Director | 28-May-2024 | Current |
Financial Performance of Aptus Pharma.
Aptus Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 32.27% increase. The company also saw a substantial improvement in profitability, with a 140.83% increase in profit. The company's net worth Soared by an impressive increase of 28.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aptus Pharma?
In 2023, Aptus Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shree Giriraj Healthcare Private LimitedActive 3 years 2 monthsRiddhish Tanna and Chetan Lalseta are mutual person
- Shree Giriraj Lifecare Private LimitedActive 6 years 7 months
Riddhish Tanna and Chetan Lalseta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Feb 2024 | ₹3.00 Cr | Open |
Hdfc Bank Limited Creation Date: 28 Apr 2023 | ₹2.00 Cr | Satisfied |
Others Creation Date: 15 Jul 2020 | ₹0.59 M | Satisfied |
How Many Employees Work at Aptus Pharma?
Aptus Pharma has a workforce of 28 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aptus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aptus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
